Loading
In the first randomised trial to show a benefit in papillary kidney cancer, the MET-targeting kinase inhibitor cabozantinib delayed progression and tripled the response rate compared with sunitinib, while two other MET inhibitors did not.
Randomised phase 2 trial of 147 patients with metastatic papillary renal cell carcinoma randomised to sunitinib, cabozantinib, crizotinib or savolitinib; the crizotinib and savolitinib arms closed early for futility.
Median progression-free survival was 9.0 months with cabozantinib against 5.6 months with sunitinib (hazard ratio 0.60) and response 23 versus 4 percent.
Cabozantinib is the preferred first-line targeted therapy for metastatic papillary renal cell carcinoma; immunotherapy combinations are being tested on top of it.
Shares Savolitinib, Papillary renal cell carcinoma, Sunitinib.
Shares Savolitinib, Papillary renal cell carcinoma, Sunitinib.
Shares Crizotinib, Cabozantinib.
Shares Papillary renal cell carcinoma, Sunitinib.
Shares Sunitinib, The Lancet.
Shares Papillary renal cell carcinoma, Sunitinib, Cabozantinib.
Shares Sunitinib, The Lancet.
Shares Sunitinib, The Lancet.